Therapeutic Asset Ratings
462 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
stp938
Neoplasm
Step Pharma, SAS
P1
C
(36)
sv-101
Neoplasm
Williams Cancer Foundation
P1
C
(36)
Tach101
Neoplasm
Tachyon Therapeutics, Inc.
P1
C
(36)
tas2940
Neoplasm
Taiho Oncology, Inc.
P1
C
(36)
TH19P01-DOCETAXEL
Neoplasm
Theratechnologies
P1
C
(36)
tj033721
Neoplasm
I-Mab Biopharma US Limited
P1
C
(36)
Tolododekin Alfa
Neoplasm
Ankyra Therapeutics, Inc
P1
C
(36)
tqb3811
Neoplasm
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
P1
C
(36)
Tyra-200
Neoplasm
Tyra Biosciences, Inc
P1
C
(36)
Uclm802 Cell
Neoplasm
Peking University
P1
C
(36)
vg2025
Neoplasm
Virogin Biotech Canada Ltd
P1
C
(36)
vrt106
Neoplasm
Guangzhou Virotech Pharmaceutical Co., Ltd.
P1
C
(36)
wbc100 bid
Neoplasm
Zhejiang University
P1
C
(36)
wbc100 qd
Neoplasm
Zhejiang University
P1
C
(36)
xb628
Neoplasm
Exelixis
P1
C
(36)
yl-13027
Neoplasm
Shanghai YingLi Pharmaceutical Co. Ltd.
P1
C
(36)
Zanzalintinib
Neoplasm
Exelixis
P1
C
(36)
Zeprumetostat
Solid Tumor
Maxivax SA
P1
C
(36)
68Ga-NODAGA-SNA006
Neoplasm
SmartNuclide Biopharma
Early P1
C
(36)
gt201
Neoplasm
RenJi Hospital
P1/2
C
(36)
18F-ASIS
Solid Tumor
Var2 Pharmaceuticals
Early P1
C
(33)
[18F]SF-DEVD-2
Neoplasm
Affiliated Hospital of Jiangnan University
Early P1
C
(33)
89zr-dfo-n-suc-c9scfv
Neoplasm
Var2 Pharmaceuticals
Early P1
C
(33)
89Zr-DFO-N-Suc-F8scFv
Neoplasm
Var2 Pharmaceuticals
Early P1
C
(33)
ABO2109
Solid Tumor
Ruijin Hospital
Early P1
C
(33)
Showing 401 to 425 of 462 assets
Previous
Page 17 of 19
Next
